3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Thymus Neoplasms
1
Neuroendocrine Tumors
1
Interventions
lutetium Lu 177 dotatate
8
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
pembrolizumab
3
olaparib
2
fludarabine
2
cabozantinib
2
X-Rays
2
Phantoms, Imaging
2
Cyclophosphamide
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
repotrectinib
1
peposertib
1
pazopanib
1
lenvatinib
1
fludarabine phosphate
1
entrectinib
1
belinostat
1
aldesleukin
1
Yttrium-90
1
Tomography, X-Ray Computed
1
Tomography, Emission-Computed, Single-Photon
1
Temozolomide
1
Single Photon Emission Computed Tomography Computed Tomography
1
Salts
1
Positron Emission Tomography Computed Tomography
1
PT-100 dipeptide
1
Octreotide
1
Nivolumab
1
Introns
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
30 days
×
Clear all
NCT05918302
2026-05-12
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Recruiting
170 enrolled